ANT2 (Adenine Nucleotide Translocator 2), encoded by the SLC25A5 gene (Solute Carrier Family 25 Member 5), is a mitochondrial inner membrane protein that catalyzes the exchange of ADP and ATP across the inner mitochondrial membrane. This carrier protein is essential for cellular energy production through oxidative phosphorylation (OXPHOS), making it fundamental to neuronal function and survival.
The adenine nucleotide translocase (ANT) family comprises four isoforms in humans (ANT1-4), each with distinct tissue expression patterns and functional characteristics. ANT2 (SLC25A5) is the dominant isoform in proliferating cells and is widely expressed in most tissues, including the brain. It plays critical roles in maintaining mitochondrial ATP export while importing ADP for oxidative phosphorylation.
ANT2 has garnered significant attention in neurodegenerative disease research due to its central position in cellular energy metabolism and its involvement in mitochondrial permeability transition pore (mPTP) formation. Dysfunction of ANT2 has been implicated in Alzheimer's disease, Parkinson's disease, and various mitochondrial disorders.
| Property |
Value |
| Gene Symbol |
SLC25A5 |
| Protein Name |
Adenine Nucleotide Translocator 2 (ANT2) |
| Alternative Names |
ADP/ATP Translocase 2, ANT2, PiC (phosphate carrier) partner |
| Chromosomal Location |
Xq26.3 |
| NCBI Gene ID |
291 |
| OMIM ID |
300120 |
| Ensembl ID |
ENSG00000148218 |
| UniProt ID |
P02724 |
| Protein Length |
322 amino acids |
| Protein Mass |
~33 kDa |
¶ Protein Structure and Function
ANT2 is a member of the mitochondrial carrier family (MCF) characterized by a unique three-domain structure :
- N-terminal domain (1-110 aa): Contains the first two transmembrane helices
- Central domain (111-210 aa): Contains the third and fourth transmembrane helices with the substrate-binding pocket
- C-terminal domain (211-322 aa): Contains the last two transmembrane helices
Each domain contains two transmembrane α-helices connected by a hydrophilic loop, forming a six-transmembrane helix structure. The threefold symmetry allows for substrate binding in a central pore formed by the helices.
ANT2 catalyzes a strict counter-exchange transport:
- ADP import: ADP from the cytosol binds to the carrier on the outer side
- Conformational change: The carrier undergoes a structural transition (from c-state to m-state)
- ATP export: ATP from the matrix is exchanged for ADP
- Return to initial state: The empty carrier returns to the original conformation
This exchange is electroneutral (one ADP in for one ATP out), maintaining the mitochondrial membrane potential while fulfilling the cell's energy demands.
ANT2 exhibits:
- High specificity: Strictly exchanges ADP and ATP
- No other substrates: Does not transport other nucleotides
- Direction: Predominantly exports ATP under normal conditions
- Inhibition: Specific inhibitors include bongkrekic acid (matrix-side) and atractyloside (cytosolic side)
ANT2 operates in multiple functional states:
- c-state (cytosolic-facing): Open to cytosolic ADP
- m-state (matrix-facing): Open to matrix ATP
- Transition state: During substrate translocation
ANT2 is essential for oxidative phosphorylation:
flowchart TD
subgraph Cytosol
ADP["ADP"]
ATP["ATP"]
end
subgraph Mitochondria
OXPHOS["OXPHOS"]
ATP_M["ATP"]
end
subgraph Inner_Membrane
ANT["ANT2"]
end
ADP --> ANT
ANT --> ATP_M
ATP_M --> ANT
ANT --> ATP
OXPHOX -.-> ATP_M
ATP --> Energy["Cellular Energy"]
- Mitochondrial matrix generates ATP via oxidative phosphorylation
- ANT2 exports ATP to the cytosol for cellular use
- Cytosolic ADP is imported for renewed ATP synthesis
- This cycle continues as long as substrates (glucose, oxygen) are available
ANT2 plays a central role in mitochondrial permeability transition pore (mPTP) formation :
- mPTP formation: Under pathological conditions, ANT2 can contribute to pore formation
- Cyclosporine A sensitivity: mPTP is inhibited by cyclosporine A
- Calcium overload: High matrix Ca2+ triggers mPTP opening
- Cell death: mPTP opening leads to mitochondrial swelling and cell death
ANT2 integrates cellular metabolic state:
- ATP/ADP ratio sensing: Transport rate responds to cellular energy status
- AMP kinase activation: Low ATP triggers AMPK signaling
- Mitochondrial respiration coupling: Matches ATP production to demand
ANT2 is implicated in apoptosis through several mechanisms :
- mPTP contribution: Opening leads to apoptosis
- Pro-apoptotic binding: Interactions with pro-apoptotic proteins
- Cytochrome c release: mPTP triggers release of apoptotic factors
ANT2 is expressed throughout the brain with high demand for energy:
| Brain Region |
Expression Level |
Notes |
| Cerebral Cortex |
High |
Pyramidal neurons |
| Hippocampus |
High |
CA1-CA3, dentate gyrus |
| Cerebellum |
High |
Purkinje cells |
| Basal Ganglia |
High |
Medium spiny neurons |
| Substantia Nigra |
High |
Dopaminergic neurons |
| Brainstem |
Moderate |
Respiratory centers |
ANT2 is expressed in:
Beyond the nervous system, ANT2 is expressed in:
- Heart (high energy demand)
- Skeletal muscle
- Liver
- Kidney
Mitochondrial dysfunction is an early hallmark of Alzheimer's disease, and ANT2 contributes to several aspects of this pathology :
- Reduced OXPHOS efficiency in AD brain
- Decreased ATP production
- Impaired glucose metabolism
- NAD+/NADH ratio alterations
Amyloid-beta (Aβ) affects ANT2 function:
- Aβ accumulates in mitochondrial membranes
- Direct interaction with ANT2 reduces activity
- Impaired ADP/ATP exchange
- Enhanced mPTP sensitivity
Tau pathology affects ANT2:
- Hyperphosphorylated tau disrupts mitochondrial transport
- Impaired distribution of ANT2-containing vesicles
- Synaptic energy failure
AD mitochondria show:
- Accumulated mtDNA mutations
- Reduced ANT2 expression
- Impaired protein import
flowchart TD
A["Aβ accumulation"] --> B["Mitochondrial dysfunction"]
B --> C["ANT2 impairment"]
C --> D["ATP deficit"]
D --> E["Synaptic failure"]
D --> F["Neuronal death"]
C --> G["mPTP sensitization"]
G --> H["Apoptosis"]
ANT2 dysfunction is strongly implicated in Parkinson's disease, particularly in dopaminergic neurons of the substantia nigra :
Dopaminergic neurons have high energy demands:
- Continuous pacemaking activity requires sustained ATP
- Mitochondrial dysfunction is a central PD mechanism
- ANT2 impairment compounds energy deficits
¶ mtDNA and PD
- mtDNA mutations accumulate in PD substantia nigra
- ANT2 gene variants may increase PD risk
- Mitochondrial complex I deficiency in PD
α-Synuclein affects ANT2:
- Mitochondrial localization of α-synuclein
- Direct interaction with ANT2
- Impaired ADP/ATP exchange
- Enhanced mPTP opening
The PINK1/Parkin mitophagy pathway intersects with ANT2:
- Damaged mitochondria have altered ANT2
- Parkin ubiquitinates ANT2
- Mitophagy removes dysfunctional carriers
Targeting ANT2 in PD:
- Metabolic support: Enhance mitochondrial function
- mPTP modulators: Prevent excessive opening
- Gene therapy: Increase ANT2 expression
ANT2 contributes to motor neuron degeneration in ALS:
- High energy demands of motor neurons
- Mitochondrial dysfunction in ALS
- mPTP hyperactivation
- Apoptosis susceptibility
- Mitochondrial dysfunction in HD
- ANT2 alterations
- Energy deficit in striatal neurons
Primary ANT2 deficiency causes:
- Mitochondrial myopathy
- Cardiomyopathy
- Encephalopathy
- Exercise intolerance
ANT2 is an essential component of the oxidative phosphorylation system:
- Complex I (NADH dehydrogenase)
- Complex II (Succinate dehydrogenase)
- Complex III (Cytochrome bc1)
- Complex IV (Cytochrome c oxidase)
- Complex V (ATP synthase)
ANT2 provides ADP for ATP synthase while exporting the generated ATP.
The mitochondrial permeability transition pore involves :
- ANT isoforms: Major component of the pore
- VDAC: Voltage-dependent anion channel
- Cyclophilin D: Regulatory component
- Other proteins: Various modulators
¶ Calcium Handling
ANT2 is involved in mitochondrial calcium dynamics:
- Calcium stimulates ATP production
- High calcium triggers mPTP
- ANT2 function is calcium-sensitive
Mitochondrial ROS production affects ANT2:
- Oxidative damage to ANT2
- Impaired function with age
- ROS-induced mPTP opening
- CoQ10: Electron transport chain support
- Alpha-lipoic acid: Mitochondrial antioxidant
- L-carnitine: Fatty acid oxidation support
- Creatine: Energy buffer
- Cyclosporine A: mPTP inhibition (in research)
- Non-immunosuppressive analogs: Therapeutic potential
- PGC-1α activators: Increase mitochondrial mass
- AMPK activators: Enhance energy metabolism
- ANT2 expression: Increase levels
- ** isoform-specific targeting**: Selective modulation
- AAV delivery: CNS-targeted
Emerging therapeutic strategies include:
- ANT-specific modulators: Direct targeting
- Allosteric effectors: Functional enhancement
- mPTP preventers: Block pathological opening
ANT2-related biomarkers:
- Serum ANT2 levels: Disease monitoring
- mPTP sensitivity: Diagnostic use
- ATP/ADP ratios: Metabolic status
- Structural studies: High-resolution ANT2 structure
- Disease mechanisms: Specific contributions to AD/PD
- Therapeutic targeting: Drug development
- Biomarkers: Disease progression markers
- Single-nucleus sequencing: Cell-type specific ANT2 expression
- CRISPR screening: Genetic interactions
- iPSC models: Patient-derived neurons
- Structural biology: Cryo-EM studies
Key questions:
- How does ANT2 specifically contribute to neurodegeneration?
- Can ANT2 be safely modulated therapeutically?
- What are the best biomarkers for ANT2-related disease?
- How do different ANT isoforms interact?
Models used to study ANT2:
- Knockout mice: Embryonic lethal (ANT1 compensates)
- Conditional knockouts: Tissue-specific deletion
- Transgenic models: Disease-associated mutations
- Drosophila: Genetic screening
¶ Genetics and Variants
SLC25A5 variants are associated with:
- X-linked mitochondrial myopathy: Severe pathogenic variants
- Modifier effects: Subtle variants in PD/AD
- Pharmacogenomics: Drug response variants
- X-linked gene location
- Males are hemizygous
- Female carriers possible
| Isoform |
Gene |
Tissue Expression |
Function |
Disease Links |
| ANT1 |
SLC25A4 |
Heart, skeletal muscle |
High OXPHOS |
Mitochondrial myopathy |
| ANT2 |
SLC25A5 |
Ubiquitous, proliferating cells |
Growth-associated |
Neurodegeneration |
| ANT3 |
SLC25A6 |
Ubiquitous |
Redundant? |
Less characterized |
| ANT4 |
SLC25A31 |
Testis |
Germ cell-specific |
Reproductive function |